1
|
Stangret A, Sadowski KA, Jabłoński K, Kochman J, Opolski G, Grabowski M, Tomaniak M. Chemokine Fractalkine and Non-Obstructive Coronary Artery Disease-Is There a Link? Int J Mol Sci 2024; 25:3885. [PMID: 38612695 PMCID: PMC11012077 DOI: 10.3390/ijms25073885] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2024] [Revised: 03/28/2024] [Accepted: 03/28/2024] [Indexed: 04/14/2024] Open
Abstract
Non-obstructive coronary artery disease (NO-CAD) constitutes a heterogeneous group of conditions collectively characterized by less than 50% narrowing in at least one major coronary artery with a fractional flow reserve (FFR) of ≤0.80 observed in coronary angiography. The pathogenesis and progression of NO-CAD are still not fully understood, however, inflammatory processes, particularly atherosclerosis and microvascular dysfunction are known to play a major role in it. Chemokine fractalkine (FKN/CX3CL1) is inherently linked to these processes. FKN/CX3CL1 functions predominantly as a chemoattractant for immune cells, facilitating their transmigration through the vessel wall and inhibiting their apoptosis. Its concentrations correlate positively with major cardiovascular risk factors. Moreover, promising preliminary results have shown that FKN/CX3CL1 receptor inhibitor (KAND567) administered in the population of patients with ST-elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI), inhibits the adverse reaction of the immune system that causes hyperinflammation. Whereas the link between FKN/CX3CL1 and NO-CAD appears evident, further studies are necessary to unveil this complex relationship. In this review, we critically overview the current data on FKN/CX3CL1 in the context of NO-CAD and present the novel clinical implications of the unique structure and function of FKN/CX3CL1 as a compound which distinctively contributes to the pathomechanism of this condition.
Collapse
Affiliation(s)
- Aleksandra Stangret
- Chair and Department of Experimental and Clinical Physiology, Laboratory of Centre for Preclinical Research, Medical University of Warsaw, Banacha 1b, 02-097 Warsaw, Poland;
| | - Karol Artur Sadowski
- 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a, 01-267 Warsaw, Poland; (K.A.S.); (K.J.); (J.K.); (G.O.); (M.G.)
| | - Konrad Jabłoński
- 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a, 01-267 Warsaw, Poland; (K.A.S.); (K.J.); (J.K.); (G.O.); (M.G.)
| | - Janusz Kochman
- 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a, 01-267 Warsaw, Poland; (K.A.S.); (K.J.); (J.K.); (G.O.); (M.G.)
| | - Grzegorz Opolski
- 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a, 01-267 Warsaw, Poland; (K.A.S.); (K.J.); (J.K.); (G.O.); (M.G.)
| | - Marcin Grabowski
- 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a, 01-267 Warsaw, Poland; (K.A.S.); (K.J.); (J.K.); (G.O.); (M.G.)
| | - Mariusz Tomaniak
- 1st Department of Cardiology, Medical University of Warsaw, Banacha 1a, 01-267 Warsaw, Poland; (K.A.S.); (K.J.); (J.K.); (G.O.); (M.G.)
| |
Collapse
|
2
|
Increased frequency of proangiogenic tunica intima endothelial kinase 2 (Tie2) expressing monocytes in individuals with type 2 diabetes mellitus. Cardiovasc Diabetol 2022; 21:72. [PMID: 35549955 PMCID: PMC9102255 DOI: 10.1186/s12933-022-01497-6] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/29/2021] [Accepted: 02/18/2022] [Indexed: 12/02/2022] Open
Abstract
Background Individuals with type 2 diabetes mellitus (T2DM) have an increased risk for developing macrovascular disease (MVD) manifested by atherosclerosis. Phenotypically and functionally different monocyte subsets (classical; CD14++CD16−, non-classical; CD14+CD16++, and intermediate; CD14++CD16+) including pro-angiogenic monocytes expressing Tie2 (TEMs) can be identified. Here we investigated monocyte heterogeneity and its association with T2DM and MVD. Methods Individuals with (N = 51) and without (N = 56) T2DM were recruited and allocated to "non-MVD" or "with MVD" (i.e., peripheral or coronary artery disease) subgroups. Blood monocyte subsets were quantified based on CD14, CD16 and Tie2 expression levels. Plasma levels of Tie2-ligands angiopoietin-1 and angiopoietin-2 were determined using ELISA. Carotid endarterectomy samples from individuals with (N = 24) and without (N = 22) T2DM were stained for intraplaque CD68+ macrophages (inflammation) and CD34+ (angiogenesis), as plaque vulnerability markers. Results Monocyte counts were similar between individuals with T2DM and healthy controls (non-diabetic, non-MVD). Non-classical monocytes were reduced (p < 0.05) in T2DM, whereas the percentage of TEMs within the intermediate subset was increased (p < 0.05). T2DM was associated with increased angiopoietin-1 (p < 0.05) and angiopoietin-2 (p = 0.0001) levels. Angiopoietin-2 levels were higher in T2DM individuals with MVD compared with non-MVD (p < 0.01). Endarterectomized plaques showed no differences in macrophage influx and microvessel number between individuals with and without T2DM. Conclusions Monocyte subset distribution is altered in T2DM with reduced non-classical monocytes and increased TEM percentage in the intermediate monocyte subset. Increased angiopoietin-2 levels together with increased frequency of TEMs might promote plaque vulnerability in T2DM which could however not be confirmed at tissue level in advanced atherosclerotic lesions.
Collapse
|
3
|
Myeloid leukocytes' diverse effects on cardiovascular and systemic inflammation in chronic kidney disease. Basic Res Cardiol 2022; 117:38. [PMID: 35896846 PMCID: PMC9329413 DOI: 10.1007/s00395-022-00945-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 06/24/2022] [Accepted: 07/11/2022] [Indexed: 01/31/2023]
Abstract
Chronic kidney disease's prevalence rises globally. Whereas dialysis treatment replaces the kidney's filtering function and prolongs life, dreaded consequences in remote organs develop inevitably over time. Even milder reductions in kidney function not requiring replacement therapy associate with bacterial infections, cardiovascular and heart valve disease, which markedly limit prognosis in these patients. The array of complications is diverse and engages a wide gamut of cellular and molecular mechanisms. The innate immune system is profoundly and systemically altered in chronic kidney disease and, as a unifying element, partakes in many of the disease's complications. As such, a derailed immune system fuels cardiovascular disease progression but also elevates the propensity for serious bacterial infections. Recent data further point towards a role in developing calcific aortic valve stenosis. Here, we delineate the current state of knowledge on how chronic kidney disease affects innate immunity in cardiovascular organs and on a systemic level. We review the role of circulating myeloid cells, monocytes and neutrophils, resident macrophages, dendritic cells, ligands, and cellular pathways that are activated or suppressed when renal function is chronically impaired. Finally, we discuss myeloid cells' varying responses to uremia from a systems immunology perspective.
Collapse
|
4
|
Angelopoulou E, Paudel YN, Shaikh MF, Piperi C. Fractalkine (CX3CL1) signaling and neuroinflammation in Parkinson’s disease: Potential clinical and therapeutic implications. Pharmacol Res 2020; 158:104930. [DOI: 10.1016/j.phrs.2020.104930] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/04/2020] [Revised: 04/16/2020] [Accepted: 05/12/2020] [Indexed: 12/14/2022]
|
5
|
Li C, Zhong X, Xia W, He J, Gan H, Zhao H, Xia Y. The CX3CL1/CX3CR1 axis is upregulated in chronic kidney disease and contributes to angiotensin II-induced migration of vascular smooth muscle cells. Microvasc Res 2020; 132:104037. [PMID: 32615135 DOI: 10.1016/j.mvr.2020.104037] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2020] [Revised: 06/10/2020] [Accepted: 06/23/2020] [Indexed: 01/20/2023]
Abstract
BACKGROUND The role of the chemokine axis, CX3CL1/CX3CR1, in the development of cardiovascular diseases has been widely speculated. Angiotensin II (Ang II) is a pivotal factor promoting cardiovascular complications in patients with chronic kidney disease (CKD). Whether there is a link between the two in CKD remains unclear. METHODS The uremic mice were treated with losartan for 8 weeks, and the expression of aortic CX3CL1/CX3CR1 was detected. Cultured mouse aortic vascular smooth muscle cells (VSMCs) were stimulated with Ang II, and then CX3CR1 expression was assessed by western blot. After the targeted disruption of CX3CR1 by transfection with siRNA, the migration of VSMCs was detected by transwell assay. Finally, both the activation of Akt pathway and the expression of IL-6 were detected by western blot. RESULTS Losartan treatment reduced the upregulation of aortic CX3CL1/CX3CR1 expression in uremic mice. In vitro, Ang II significantly upregulated CX3CR1 expression in VSMCs. Targeted disruption of CX3CR1 attenuated Ang II-induced migration of VSMCs. In addition, the use of CX3CR1-siRNA suppressed Akt phosphorylation and IL-6 production in VSMCs stimulated by Ang II. CONCLUSIONS The aortic CX3CL1/CX3CR1 is upregulated by Ang II in CKD, and it contributes to Ang II-induced migration of VSMCs in vitro.
Collapse
MESH Headings
- Angiotensin II/pharmacology
- Animals
- Aorta/drug effects
- Aorta/metabolism
- Aorta/pathology
- CX3C Chemokine Receptor 1/genetics
- CX3C Chemokine Receptor 1/metabolism
- Cell Line
- Cell Movement/drug effects
- Chemokine CX3CL1/genetics
- Chemokine CX3CL1/metabolism
- Disease Models, Animal
- Interleukin-6/metabolism
- Mice, Inbred C57BL
- Muscle, Smooth, Vascular/drug effects
- Muscle, Smooth, Vascular/metabolism
- Muscle, Smooth, Vascular/pathology
- Myocytes, Smooth Muscle/drug effects
- Myocytes, Smooth Muscle/metabolism
- Myocytes, Smooth Muscle/pathology
- Phosphorylation
- Proto-Oncogene Proteins c-akt/metabolism
- Renal Insufficiency, Chronic/metabolism
- Renal Insufficiency, Chronic/pathology
- Signal Transduction
- Up-Regulation
- Uremia/metabolism
- Uremia/pathology
Collapse
Affiliation(s)
- Chengsheng Li
- Department of General Internal Medicine, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou 510080, China
| | - Xiaoyi Zhong
- Department of Nephrology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - Wenyu Xia
- Class 4, Grade 2, Guangzhou Zhixin High School, Guangzhou 511430, China
| | - Jin He
- Department of Nephrology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - Hua Gan
- Department of Nephrology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China
| | - HongFei Zhao
- Department of Nephrology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
| | - Yunfeng Xia
- Department of Nephrology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.
| |
Collapse
|
6
|
Aspirin in stroke patients modifies the immunomodulatory interactions of marrow stromal cells and monocytes. Brain Res 2019; 1720:146298. [PMID: 31220426 DOI: 10.1016/j.brainres.2019.06.017] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2019] [Revised: 06/14/2019] [Accepted: 06/15/2019] [Indexed: 12/15/2022]
Abstract
BACKGROUND AND OBJECTIVE Most stroke patients are prescribed aspirin (ASA) to adjust blood coagulability. Marrow stromal cells (MSCs) are being tested in clinical trials for stroke patients who likely are prescribed aspirin. One of the principal mechanisms of action of MSCs and ASA is modulation of the inflammatory response, including those mediated by monocytes (Mo). Thus, here we tested if aspirin can modify anti-inflammatory properties of MSCs or Mo alone, and in combination. METHODS Mo were isolated at 24 h of stroke onset from ischemic stroke patients with NIHSS ranging from 11 to 20 or from healthy controls. Human bone marrow-derived MSCs from healthy subjects were used at passage 3. Mo, MSCs, and MSCs-Mo co-cultures were exposed to ASA at clinically relevant doses. The secretome profile of inflammatory mediators was measured using Magpix multiplex cytokine array. Viability was measured using MTT assay. Linear mixed effect model was used for statistical analysis. RESULTS Overall Mo from control subjects exposed to ASA showed increased secretion of IL-1RA, IL-8, MCP-1, and TNF-α and Mo from stroke patients showed greater release of IL-1RA and MCP-1. In MSCs-Mo co-cultures, ASA added to co-cultures of control Mo reduced fractalkine secretion while it increased the fractalkine secretion when added to Mo from stroke patients. In addition, in co-cultures independent of Mo origin, ASA reduced IL-6, IL-8, MCP-1, and TNF-α. CONCLUSIONS Aspirin in acute stroke patients may modulate the secretome profile of Mo and MSCs, thus potentially modulating immune and inflammatory responses associated with stroke. Our results suggest that stroke trials involving the use of intravenous MSCs should consider the effect of aspirin as a confounding factor.
Collapse
|
7
|
Ishizuka K, Fujita Y, Kawabata T, Kimura H, Iwayama Y, Inada T, Okahisa Y, Egawa J, Usami M, Kushima I, Uno Y, Okada T, Ikeda M, Aleksic B, Mori D, Someya T, Yoshikawa T, Iwata N, Nakamura H, Yamashita T, Ozaki N. Rare genetic variants in CX3CR1 and their contribution to the increased risk of schizophrenia and autism spectrum disorders. Transl Psychiatry 2017; 7:e1184. [PMID: 28763059 PMCID: PMC5611740 DOI: 10.1038/tp.2017.173] [Citation(s) in RCA: 50] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/09/2017] [Revised: 05/20/2017] [Accepted: 06/17/2017] [Indexed: 12/20/2022] Open
Abstract
CX3CR1, a G protein-coupled receptor solely expressed by microglia in the brain, has been repeatedly reported to be associated with neurodevelopmental disorders including schizophrenia (SCZ) and autism spectrum disorders (ASD) in transcriptomic and animal studies but not in genetic studies. To address the impacts of variants in CX3CR1 on neurodevelopmental disorders, we conducted coding exon-targeted resequencing of CX3CR1 in 370 Japanese SCZ and 192 ASD patients using next-generation sequencing technology, followed by a genetic association study in a sample comprising 7054 unrelated individuals (2653 SCZ, 574 ASD and 3827 controls). We then performed in silico three-dimensional (3D) structural modeling and in vivo disruption of Akt phosphorylation to determine the impact of the detected variant on CX3CR1-dependent signal transduction. We detected a statistically significant association between the variant Ala55Thr in CX3CR1 with SCZ and ASD phenotypes (odds ratio=8.3, P=0.020). A 3D structural model indicated that Ala55Thr could destabilize the conformation of the CX3CR1 helix 8 and affect its interaction with a heterotrimeric G protein. In vitro functional analysis showed that the CX3CR1-Ala55Thr mutation inhibited cell signaling induced by fractalkine, the ligand for CX3CR1. The combined data suggested that the variant Ala55Thr in CX3CR1 might result in the disruption of CX3CR1 signaling. Our results strengthen the association between microglia-specific genes and neurodevelopmental disorders.
Collapse
Affiliation(s)
- K Ishizuka
- Department of Psychiatry, Nagoya
University Graduate School of Medicine, Nagoya,
Japan
| | - Y Fujita
- Department of Molecular Neuroscience,
Osaka University Graduate School of Medicine, Osaka,
Japan
| | - T Kawabata
- Institute for Protein Research, Osaka
University, Osaka, Japan
| | - H Kimura
- Department of Psychiatry, Nagoya
University Graduate School of Medicine, Nagoya,
Japan
| | - Y Iwayama
- Laboratory for Molecular Psychiatry,
RIKEN Brain Science Institute, Wako, Japan
| | - T Inada
- Department of Psychiatry, Nagoya
University Graduate School of Medicine, Nagoya,
Japan
| | - Y Okahisa
- Department of Neuropsychiatry, Okayama
University Graduate School of Medicine, Dentistry and Pharmaceutical
Sciences, Okayama, Japan
| | - J Egawa
- Department of Psychiatry, Niigata
University Graduate School of Medical and Dental Sciences,
Niigata, Japan
| | - M Usami
- Department of Child and Adolescent
Psychiatry, Kohnodai Hospital, National Center for Global Health and
Medicine, Ichikawa, Japan
| | - I Kushima
- Department of Psychiatry, Nagoya
University Graduate School of Medicine, Nagoya,
Japan
| | - Y Uno
- Department of Psychiatry, Nagoya
University Graduate School of Medicine, Nagoya,
Japan,Laboratory for Psychiatric and Molecular
Neuroscience, McLean Hospital, Belmont, MA,
USA
| | - T Okada
- Department of Psychiatry, Nagoya
University Graduate School of Medicine, Nagoya,
Japan
| | - M Ikeda
- Department of Psychiatry, Fujita Health
University School of Medicine, Toyoake, Japan
| | - B Aleksic
- Department of Psychiatry, Nagoya
University Graduate School of Medicine, Nagoya,
Japan,Department of Psychiatry, Nagoya University Graduate School
of Medicine, 65 Tsurumai-cho, Showa-ku,
Nagoya, Aichi
4668550, Japan. E-mail:
| | - D Mori
- Department of Psychiatry, Nagoya
University Graduate School of Medicine, Nagoya,
Japan,Brain and Mind Research Center, Nagoya
University, Nagoya, Japan
| | - To Someya
- Department of Psychiatry, Niigata
University Graduate School of Medical and Dental Sciences,
Niigata, Japan
| | - T Yoshikawa
- Laboratory for Molecular Psychiatry,
RIKEN Brain Science Institute, Wako, Japan
| | - N Iwata
- Department of Psychiatry, Fujita Health
University School of Medicine, Toyoake, Japan
| | - H Nakamura
- Institute for Protein Research, Osaka
University, Osaka, Japan
| | - T Yamashita
- Department of Molecular Neuroscience,
Osaka University Graduate School of Medicine, Osaka,
Japan
| | - N Ozaki
- Department of Psychiatry, Nagoya
University Graduate School of Medicine, Nagoya,
Japan
| |
Collapse
|
8
|
Biel NM, Santostefano KE, DiVita BB, El Rouby N, Carrasquilla SD, Simmons C, Nakanishi M, Cooper-DeHoff RM, Johnson JA, Terada N. Vascular Smooth Muscle Cells From Hypertensive Patient-Derived Induced Pluripotent Stem Cells to Advance Hypertension Pharmacogenomics. Stem Cells Transl Med 2015; 4:1380-90. [PMID: 26494780 PMCID: PMC4675511 DOI: 10.5966/sctm.2015-0126] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2015] [Accepted: 08/31/2015] [Indexed: 12/12/2022] Open
Abstract
UNLABELLED Studies in hypertension (HTN) pharmacogenomics seek to identify genetic sources of variable antihypertensive drug response. Genetic association studies have detected single-nucleotide polymorphisms (SNPs) that link to drug responses; however, to understand mechanisms underlying how genetic traits alter drug responses, a biological interface is needed. Patient-derived induced pluripotent stem cells (iPSCs) provide a potential source for studying otherwise inaccessible tissues that may be important to antihypertensive drug response. The present study established multiple iPSC lines from an HTN pharmacogenomics cohort. We demonstrated that established HTN iPSCs can robustly and reproducibly differentiate into functional vascular smooth muscle cells (VSMCs), a cell type most relevant to vasculature tone control. Moreover, a sensitive traction force microscopy assay demonstrated that iPSC-derived VSMCs show a quantitative contractile response on physiological stimulus of endothelin-1. Furthermore, the inflammatory chemokine tumor necrosis factor α induced a typical VSMC response in iPSC-derived VSMCs. These studies pave the way for a large research initiative to decode biological significance of identified SNPs in hypertension pharmacogenomics. SIGNIFICANCE Treatment of hypertension remains suboptimal, and a pharmacogenomics approach seeks to identify genetic biomarkers that could be used to guide treatment decisions; however, it is important to understand the biological underpinnings of genetic associations. Mouse models do not accurately recapitulate individual patient responses based on their genetics, and hypertension-relevant cells are difficult to obtain from patients. Induced pluripotent stem cell (iPSC) technology provides a great interface to bring patient cells with their genomic data into the laboratory and to study hypertensive responses. As an initial step, the present study established an iPSC bank from patients with primary hypertension and demonstrated an effective and reproducible method of generating functional vascular smooth muscle cells.
Collapse
Affiliation(s)
- Nikolett M. Biel
- Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA
- Center for Cellular Reprogramming, University of Florida, Gainesville, Florida, USA
| | - Katherine E. Santostefano
- Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA
- Center for Cellular Reprogramming, University of Florida, Gainesville, Florida, USA
| | - Bayli B. DiVita
- Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA
- Center for Cellular Reprogramming, University of Florida, Gainesville, Florida, USA
| | - Nihal El Rouby
- Department of Pharmacotherapy and Translational Research, College of Pharmacy and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA
| | - Santiago D. Carrasquilla
- J. Crayton Pruitt Family Department of Biomedical Engineering, College of Engineering, University of Florida, Gainesville, Florida, USA
| | - Chelsey Simmons
- Mechanical and Aerospace Engineering, College of Engineering, University of Florida, Gainesville, Florida, USA
- Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA
| | - Mahito Nakanishi
- Biotechnology Research Institute for Drug Discovery, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Japan
| | - Rhonda M. Cooper-DeHoff
- Department of Pharmacotherapy and Translational Research, College of Pharmacy and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA
- Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA
| | - Julie A. Johnson
- Department of Pharmacotherapy and Translational Research, College of Pharmacy and Center for Pharmacogenomics, University of Florida, Gainesville, Florida, USA
- Division of Cardiovascular Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA
| | - Naohiro Terada
- Department of Pathology, Immunology, and Laboratory Medicine, College of Medicine, University of Florida, Gainesville, Florida, USA
- Center for Cellular Reprogramming, University of Florida, Gainesville, Florida, USA
| |
Collapse
|
9
|
Zhao W, Lu H, Wang X, Ransohoff RM, Zhou L. CX3CR1 deficiency delays acute skeletal muscle injury repair by impairing macrophage functions. FASEB J 2015; 30:380-93. [PMID: 26443824 DOI: 10.1096/fj.14-270090] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2015] [Accepted: 09/14/2015] [Indexed: 12/22/2022]
Abstract
Adequate inflammatory response predominated by macrophage infiltration is essential to acute skeletal muscle injury repair. The majority of intramuscular macrophages express the chemokine receptor CX3CR1. We studied the role of CX3CR1 in regulating intramuscular macrophage number and function in acute injury repair by using a loss-of-function approach. Muscle injury repair was delayed in CX3CR1(GFP/GFP) mice as compared with wild-type (WT) controls. CX3CR1 was predominantly expressed by macrophages but not by myogenic cells or capillary endothelia cells in injured muscles. Intramuscular macrophage number and subset composition were not altered by CX3CR1 deficiency. Intramuscular macrophage phagocytosis function was impaired by CX3CR1 deficiency as demonstrated by increased number of necrotic fibers (+115%) and percentage of necrotic area (+204%) at 7 d, increased number of intramuscular neutrophils at 3 (+89%) but not 1 d, reduced number of phagocytosing macrophages (-12%) and phagocytosed beads within macrophages (-15%) in CX3CR1(GFP/GFP) mice as compared with WT controls. The mRNA expression of CD36 (-50%), CD14 (-43%), IGF-1 (-53%), and IL-6 (-40%) was reduced in CX3CR1-deficient macrophages as compared with WT controls. We conclude that CX3CR1 is important to acute skeletal muscle injury repair by regulating macrophage phagocytosis function and trophic growth factor production.
Collapse
Affiliation(s)
- Wanming Zhao
- *Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA; and Department of Neurosciences, Neuroinflammation Research Center, Cleveland Clinic, Cleveland, Ohio, USA
| | - Haiyan Lu
- *Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA; and Department of Neurosciences, Neuroinflammation Research Center, Cleveland Clinic, Cleveland, Ohio, USA
| | - Xingyu Wang
- *Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA; and Department of Neurosciences, Neuroinflammation Research Center, Cleveland Clinic, Cleveland, Ohio, USA
| | - Richard M Ransohoff
- *Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA; and Department of Neurosciences, Neuroinflammation Research Center, Cleveland Clinic, Cleveland, Ohio, USA
| | - Lan Zhou
- *Department of Neurology, Mount Sinai School of Medicine, New York, New York, USA; and Department of Neurosciences, Neuroinflammation Research Center, Cleveland Clinic, Cleveland, Ohio, USA
| |
Collapse
|
10
|
Poupel L, Boissonnas A, Hermand P, Dorgham K, Guyon E, Auvynet C, Charles FS, Lesnik P, Deterre P, Combadiere C. Pharmacological inhibition of the chemokine receptor, CX3CR1, reduces atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2013; 33:2297-305. [PMID: 23887641 DOI: 10.1161/atvbaha.112.300930] [Citation(s) in RCA: 58] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE Alterations of the chemokine receptor CX3CR1 gene were associated with a reduced risk of myocardial infarction in human and limited atherosclerosis in mice. In this study, we addressed whether CX3CR1 antagonists are potential therapeutic tools to limit acute and chronic inflammatory processes in atherosclerosis. APPROACH AND RESULTS Treatment with F1, an amino terminus-modified CX3CR1 ligand endowed with CX3CR1 antagonist activity, reduced the extent of atherosclerotic lesions in both Apoe(-/-) and Ldlr(-/-) proatherogenic mouse models. Macrophage accumulation in the aortic sinus was reduced in F1-treated Apoe(-/-) mice but the macrophage density of the lesions was similar in F1-treated and control mice. Both in vitro and in vivo F1 treatment reduced CX3CR1-dependent inflammatory monocyte adhesion, potentially limiting their recruitment. In addition, F1-treated Apoe(-/-) mice displayed reduced numbers of blood inflammatory monocytes, whereas resident monocyte numbers remained unchanged. Both in vitro and in vivo F1 treatment reduced CX3CR1-dependent inflammatory monocyte survival. Finally, F1 treatment of Apoe(-/-) mice with advanced atherosclerosis led to smaller lesions than untreated mice but without reverting to the initial phenotype. CONCLUSIONS The CX3CR1 antagonist F1 is a potent inhibitor of the progression of atherosclerotic lesions by means of its selective impact on inflammatory monocyte functions. Controlling monocyte trafficking and survival may be an alternative or complementary therapy to lipid-lowering drugs classically used in the treatment of atherosclerosis.
Collapse
Affiliation(s)
- Lucie Poupel
- From UMR_S 945, Laboratoire "Immunité et Infection," Inserm Paris, France and Université Pierre et Marie Curie- (UPMC) Paris 6, Paris, France (L.P., A.B., P.H., K.D., E.G., C.A., P.D., C.C.); UMR_S 939 P.LUMR_S 939, Laboratoire "Dyslipidémies, Inflammation et Athérosclérose," Paris, France (F.S.C., P.L.); and AP-HP, Groupe Hospitalier Pitié-Salpétrière, Service d'Immunologie, Paris, France (C.C.)
| | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Abstract
PURPOSE OF REVIEW To highlight the fact that regional differences in the normal arterial intima are critical to atherosclerotic lesion formation driven by systemic risk factors. RECENT FINDINGS At arterial curvatures, bifurcations and branches unique hemodynamics influence endothelial cell signaling and gene expression patterns, which create a proinflammatory environment, with low-grade recruitment of monocytes and accumulation of cells with dendritic features in the intima. Upon induction of hypercholesterolemia, these resident intimal dendritic cells initiate atherosclerosis by rapidly engulfing lipid and becoming the first foam cells in nascent lesions. This step precedes endothelial cell activation and increased monocyte recruitment. SUMMARY The unique features of the arterial intima at atherosclerosis-susceptible sites do not lead to disease under normal physiological conditions, but this intimal environment promotes the initiation of atherogenesis upon induction of systemic risk factors such as hypercholesterolemia.
Collapse
Affiliation(s)
- Myron I Cybulsky
- Toronto General Research Institute, University Health Network, University of Toronto, Toronto, Ontario, Canada.
| | | |
Collapse
|
12
|
Silencing CX3CR1 production modulates the interaction between dendritic and endothelial cells. Mol Biol Rep 2010; 38:481-8. [PMID: 20364328 DOI: 10.1007/s11033-010-0131-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2009] [Accepted: 03/23/2010] [Indexed: 10/19/2022]
Abstract
CX3CR1, an important chemokine receptor in dendritic cells (DCs), is linked to the progression of atherosclerotic plaques. However, the mechanism(s) determining the role of CX3CR1 in atherosclerosis have not been clearly elucidated. In this study, we developed DCs from monocytes of Sprague-Dawley (SD) rats in the presence of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) and recombinant human interleukin-4 (IL-4). The presence of recombinant human TNF-α and LPS forced the cells to mature. When compared to immature DCs, flow cytometry (FACS) analysis revealed that mature DCs display a sustained increase in the levels of CD11c, CD86, and CD80 expression. The expression of Fractalkine (FKN) in endothelial cells (ECs) contributes to the maturation of DCs and expression of CX3CR1. We revealed that mRNA expression levels of CX3CR1 in mature DCs are significantly higher than those of immature DCs (P<0.001). Transfection of DCs with siRNA specific for the CX3CR1 gene resulted in potent suppression of gene expression and inhibition of interactions between DCs and ECs. Based on these data, we hypothesized that CX3CR1 contributes to the DC-EC interaction. CX3CR1 may serve as a new target molecule for increasing therapeutic interactions in atherosclerosis.
Collapse
|
13
|
Stepanian A, Benchenni S, Beillat-Lucas T, Omnes S, Defay F, Peynaud-Debayle E, Baron G, Le Querrec A, Dreyfus M, Salomon L, Tsatsaris V, de Prost D, Mandelbrot L. Search for an association between V249I and T280M CX3CR1 genetic polymorphisms, endothelial injury and preeclampsia: the ECLAXIR study. PLoS One 2009; 4:e6192. [PMID: 19587779 PMCID: PMC2702686 DOI: 10.1371/journal.pone.0006192] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2009] [Accepted: 06/08/2009] [Indexed: 11/18/2022] Open
Abstract
BACKGROUND Preeclampsia and coronary-artery disease share risk factors, suggesting common pathophysiological mechanisms. CX3CR1/CX3CL1 mediates leukocyte migration and adhesion and has been implicated in the pathophysiology of several inflammatory diseases. M280/I249 variants of CX3CR1 are associated with an atheroprotective effect and reduced endothelial dysfunction. The aim of this study was to search for an association between V249I and T280M polymorphisms of CX3CR1, preeclampsia and endothelial dysfunction. METHODOLOGY/PRINCIPAL FINDINGS We explored these polymorphisms with real-time polymerase chain reaction in a case-control study (184 white women with preeclampsia and 184 matched normotensive pregnant women). Endothelial dysfunction biomarkers including von Willebrand factor, VCAM-1 and thrombomodulin, as well as the soluble form of CX3CL1 were measured by enzyme-linked immunosorbent assays (ELISA). The I249 and M280 alleles were associated neither with preeclampsia, nor with its more severe form or with endothelial injury. In contrast, we found a trend toward increased CX3CL1 levels in preeclampsia patients, especially in early-onset- preeclampsia as compared to its level in later-onset- preeclampsia. CONCLUSIONS/SIGNIFICANCE This is the first study to characterize the CX3CR1 gene polymorphisms in patients with preeclampsia. We found no differences in genotype or haplotype frequencies between patients with PE and normal pregnancies, suggesting that maternal CX3CR1 V249I and T280M polymorphisms do not increase susceptibility to preeclampsia. Further studies should be performed to directly evaluate the pathophysiological role of CX3CL1, a molecule abundantly expressed in endometrium, which has been shown to stimulate human trophoblast migration.
Collapse
Affiliation(s)
- Alain Stepanian
- AP-HP, Hôpital Louis Mourier, Service d'Hématologie Biologique, Colombes, France
- CIB Phénogen du GHU Nord, Paris, France
| | - Soraya Benchenni
- AP-HP, Hôpital Louis Mourier, Service d'Hématologie Biologique, Colombes, France
| | - Tiphaine Beillat-Lucas
- CHU Clémenceau, Unité de Gynécologie-Obstétrique et Médecine de la Reproduction, Caen, France
| | - Sophie Omnes
- AP-HP, Hôpital Bichat-Claude-Bernard, Service de Gynécologie-Obstétrique, Paris, France
| | - Fannie Defay
- AP-HP, Hôpital Bichat-Claude Bernard, Département d'Epidémiologie, Biostatistique et Recherche Clinique, Paris, France
| | - Edith Peynaud-Debayle
- AP-HP, Hôpital Louis Mourier, Service d'Hématologie Biologique, Colombes, France
- CIB Phénogen du GHU Nord, Paris, France
| | - Gabriel Baron
- AP-HP, Hôpital Bichat-Claude Bernard, Département d'Epidémiologie, Biostatistique et Recherche Clinique, Paris, France
| | - Agnès Le Querrec
- CHU Côte de Nacre, Service d'Hématologie Biologique, Caen, France
| | - Michel Dreyfus
- CHU Clémenceau, Unité de Gynécologie-Obstétrique et Médecine de la Reproduction, Caen, France
| | - Laurence Salomon
- AP-HP, Hôpital Louis Mourier, Département de Santé Publique (Evaluation, Recherche Clinique, Information médicale, Vigilances)–(DIM), Colombes, France
| | - Vassilis Tsatsaris
- AP-HP, Groupe Hospitalier Cochin Saint-Vincent de Paul, Service de Gynécologie-Obstétrique, Paris, France
| | - Dominique de Prost
- AP-HP, Hôpital Louis Mourier, Service d'Hématologie Biologique, Colombes, France
- CIB Phénogen du GHU Nord, Paris, France
- Université Paris 7–Denis Diderot, Paris, France
| | - Laurent Mandelbrot
- AP-HP, Hôpital Louis Mourier, Service de Gynécologie-Obstétrique, Colombes, France
- Université Paris 7–Denis Diderot, Paris, France
| | | |
Collapse
|
14
|
Hess S, Methe H, Kim JO, Edelman ER. NF-kappaB activity in endothelial cells is modulated by cell substratum interactions and influences chemokine-mediated adhesion of natural killer cells. Cell Transplant 2009; 18:261-73. [PMID: 19558775 PMCID: PMC2857529 DOI: 10.3727/096368909788534979] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Because changes in subendothelial matrix composition are associated with alterations of the endothelial immune phenotype, we sought to understand if cytokine-induced NF-kappaB activity and downstream effects depend on substrate adherence of endothelial cells (EC). We compared the upstream phosphorylation cascade, activation of NF-kappaB, and expression/secretion of downstream effects of EC grown on tissue culture polystyrene plates (TCPS) with EC embedded within collagen-based matrices (MEEC). Adhesion of natural killer (NK) cells was quantified in vitro and in vivo. NF-kappaB subunit p65 nuclear levels were significantly lower and p50 significantly higher in cytokine-stimulated MEEC than in EC-TCPS. Despite similar surface expression of TNF-alpha receptors, MEEC had significantly decreased secretion and expression of IL-6, IL-8, MCP-1, VCAM-1, and ICAM-1. Attenuated fractalkine expression and secretion in MEEC (two to threefold lower than in EC-TCPS; p < 0.0002) correlated with 3.7-fold lower NK cell adhesion to EC (6,335 +/- 420 vs. 1,735 +/- 135 cpm; p < 0.0002). Furthermore, NK cell infiltration into sites of EC implantation in vivo was significantly reduced when EC were embedded within matrix. Matrix embedding enables control of EC substratum interaction. This in turn regulates chemokine and surface molecule expression and secretion, in particular of those compounds within NF-kappaB pathways, chemoattraction of NK cells, local inflammation, and tissue repair.
Collapse
Affiliation(s)
- Shmuel Hess
- Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, USA; Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
| | | | | | | |
Collapse
|
15
|
Tacke F, Alvarez D, Kaplan TJ, Jakubzick C, Spanbroek R, Llodra J, Garin A, Liu J, Mack M, van Rooijen N, Lira SA, Habenicht AJ, Randolph GJ. Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaques. J Clin Invest 2007; 117:185-94. [PMID: 17200718 PMCID: PMC1716202 DOI: 10.1172/jci28549] [Citation(s) in RCA: 1043] [Impact Index Per Article: 61.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2006] [Accepted: 10/24/2006] [Indexed: 12/12/2022] Open
Abstract
Monocytes participate critically in atherosclerosis. There are 2 major subsets expressing different chemokine receptor patterns: CCR2(+)CX3CR1(+)Ly-6C(hi) and CCR2(-)CX3CR1(++)Ly-6C(lo) monocytes. Both C-C motif chemokine receptor 2 (CCR2) and C-X(3)-C motif chemokine receptor 1 (CX3CR1) are linked to progression of atherosclerotic plaques. Here, we analyzed mouse monocyte subsets in apoE-deficient mice and traced their differentiation and chemokine receptor usage as they accumulated within atherosclerotic plaques. Blood monocyte counts were elevated in apoE(-/-) mice and skewed toward an increased frequency of CCR2(+)Ly-6C(hi) monocytes in apoE(-/-) mice fed a high-fat diet. CCR2(+)Ly-6C(hi) monocytes efficiently accumulated in plaques, whereas CCR2(-)Ly-6C(lo) monocytes entered less frequently but were more prone to developing into plaque cells expressing the dendritic cell-associated marker CD11c, indicating that phagocyte heterogeneity in plaques is linked to distinct types of entering monocytes. CCR2(-) monocytes did not rely on CX3CR1 to enter plaques. Instead, they were partially dependent upon CCR5, which they selectively upregulated in apoE(-/-) mice. By comparison, CCR2(+)Ly-6C(hi) monocytes unexpectedly required CX3CR1 in addition to CCR2 and CCR5 to accumulate within plaques. In many other inflammatory settings, these monocytes utilize CCR2, but not CX3CR1, for trafficking. Thus, antagonizing CX3CR1 may be effective therapeutically in ameliorating CCR2(+) monocyte recruitment to plaques without impairing their CCR2-dependent responses to inflammation overall.
Collapse
Affiliation(s)
- Frank Tacke
- Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York, USA.
Institute for Vascular Medicine, Friedrich-Schiller-University, Jena, Germany.
Department of Immunobiology, Icahn Medical Institute, and
The Recanati/Miller Transplantation Institute, Mount Sinai School of Medicine, New York, New York, USA.
Department of Internal Medicine, University Clinic, University of Regensburg, Regensburg, Germany.
Department of Molecular Cell Biology, Free University Medical Center, Amsterdam, The Netherlands
| | - David Alvarez
- Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York, USA.
Institute for Vascular Medicine, Friedrich-Schiller-University, Jena, Germany.
Department of Immunobiology, Icahn Medical Institute, and
The Recanati/Miller Transplantation Institute, Mount Sinai School of Medicine, New York, New York, USA.
Department of Internal Medicine, University Clinic, University of Regensburg, Regensburg, Germany.
Department of Molecular Cell Biology, Free University Medical Center, Amsterdam, The Netherlands
| | - Theodore J. Kaplan
- Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York, USA.
Institute for Vascular Medicine, Friedrich-Schiller-University, Jena, Germany.
Department of Immunobiology, Icahn Medical Institute, and
The Recanati/Miller Transplantation Institute, Mount Sinai School of Medicine, New York, New York, USA.
Department of Internal Medicine, University Clinic, University of Regensburg, Regensburg, Germany.
Department of Molecular Cell Biology, Free University Medical Center, Amsterdam, The Netherlands
| | - Claudia Jakubzick
- Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York, USA.
Institute for Vascular Medicine, Friedrich-Schiller-University, Jena, Germany.
Department of Immunobiology, Icahn Medical Institute, and
The Recanati/Miller Transplantation Institute, Mount Sinai School of Medicine, New York, New York, USA.
Department of Internal Medicine, University Clinic, University of Regensburg, Regensburg, Germany.
Department of Molecular Cell Biology, Free University Medical Center, Amsterdam, The Netherlands
| | - Rainer Spanbroek
- Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York, USA.
Institute for Vascular Medicine, Friedrich-Schiller-University, Jena, Germany.
Department of Immunobiology, Icahn Medical Institute, and
The Recanati/Miller Transplantation Institute, Mount Sinai School of Medicine, New York, New York, USA.
Department of Internal Medicine, University Clinic, University of Regensburg, Regensburg, Germany.
Department of Molecular Cell Biology, Free University Medical Center, Amsterdam, The Netherlands
| | - Jaime Llodra
- Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York, USA.
Institute for Vascular Medicine, Friedrich-Schiller-University, Jena, Germany.
Department of Immunobiology, Icahn Medical Institute, and
The Recanati/Miller Transplantation Institute, Mount Sinai School of Medicine, New York, New York, USA.
Department of Internal Medicine, University Clinic, University of Regensburg, Regensburg, Germany.
Department of Molecular Cell Biology, Free University Medical Center, Amsterdam, The Netherlands
| | - Alexandre Garin
- Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York, USA.
Institute for Vascular Medicine, Friedrich-Schiller-University, Jena, Germany.
Department of Immunobiology, Icahn Medical Institute, and
The Recanati/Miller Transplantation Institute, Mount Sinai School of Medicine, New York, New York, USA.
Department of Internal Medicine, University Clinic, University of Regensburg, Regensburg, Germany.
Department of Molecular Cell Biology, Free University Medical Center, Amsterdam, The Netherlands
| | - Jianhua Liu
- Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York, USA.
Institute for Vascular Medicine, Friedrich-Schiller-University, Jena, Germany.
Department of Immunobiology, Icahn Medical Institute, and
The Recanati/Miller Transplantation Institute, Mount Sinai School of Medicine, New York, New York, USA.
Department of Internal Medicine, University Clinic, University of Regensburg, Regensburg, Germany.
Department of Molecular Cell Biology, Free University Medical Center, Amsterdam, The Netherlands
| | - Matthias Mack
- Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York, USA.
Institute for Vascular Medicine, Friedrich-Schiller-University, Jena, Germany.
Department of Immunobiology, Icahn Medical Institute, and
The Recanati/Miller Transplantation Institute, Mount Sinai School of Medicine, New York, New York, USA.
Department of Internal Medicine, University Clinic, University of Regensburg, Regensburg, Germany.
Department of Molecular Cell Biology, Free University Medical Center, Amsterdam, The Netherlands
| | - Nico van Rooijen
- Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York, USA.
Institute for Vascular Medicine, Friedrich-Schiller-University, Jena, Germany.
Department of Immunobiology, Icahn Medical Institute, and
The Recanati/Miller Transplantation Institute, Mount Sinai School of Medicine, New York, New York, USA.
Department of Internal Medicine, University Clinic, University of Regensburg, Regensburg, Germany.
Department of Molecular Cell Biology, Free University Medical Center, Amsterdam, The Netherlands
| | - Sergio A. Lira
- Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York, USA.
Institute for Vascular Medicine, Friedrich-Schiller-University, Jena, Germany.
Department of Immunobiology, Icahn Medical Institute, and
The Recanati/Miller Transplantation Institute, Mount Sinai School of Medicine, New York, New York, USA.
Department of Internal Medicine, University Clinic, University of Regensburg, Regensburg, Germany.
Department of Molecular Cell Biology, Free University Medical Center, Amsterdam, The Netherlands
| | - Andreas J. Habenicht
- Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York, USA.
Institute for Vascular Medicine, Friedrich-Schiller-University, Jena, Germany.
Department of Immunobiology, Icahn Medical Institute, and
The Recanati/Miller Transplantation Institute, Mount Sinai School of Medicine, New York, New York, USA.
Department of Internal Medicine, University Clinic, University of Regensburg, Regensburg, Germany.
Department of Molecular Cell Biology, Free University Medical Center, Amsterdam, The Netherlands
| | - Gwendalyn J. Randolph
- Department of Gene and Cell Medicine, Mount Sinai School of Medicine, New York, New York, USA.
Institute for Vascular Medicine, Friedrich-Schiller-University, Jena, Germany.
Department of Immunobiology, Icahn Medical Institute, and
The Recanati/Miller Transplantation Institute, Mount Sinai School of Medicine, New York, New York, USA.
Department of Internal Medicine, University Clinic, University of Regensburg, Regensburg, Germany.
Department of Molecular Cell Biology, Free University Medical Center, Amsterdam, The Netherlands
| |
Collapse
|
16
|
Cardona AE, Pioro EP, Sasse ME, Kostenko V, Cardona SM, Dijkstra IM, Huang D, Kidd G, Dombrowski S, Dutta R, Lee JC, Cook DN, Jung S, Lira SA, Littman DR, Ransohoff RM. Control of microglial neurotoxicity by the fractalkine receptor. Nat Neurosci 2006; 9:917-24. [PMID: 16732273 DOI: 10.1038/nn1715] [Citation(s) in RCA: 1132] [Impact Index Per Article: 62.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2006] [Accepted: 05/05/2006] [Indexed: 01/22/2023]
Abstract
Microglia, the resident inflammatory cells of the CNS, are the only CNS cells that express the fractalkine receptor (CX3CR1). Using three different in vivo models, we show that CX3CR1 deficiency dysregulates microglial responses, resulting in neurotoxicity. Following peripheral lipopolysaccharide injections, Cx3cr1-/- mice showed cell-autonomous microglial neurotoxicity. In a toxic model of Parkinson disease and a transgenic model of amyotrophic lateral sclerosis, Cx3cr1-/- mice showed more extensive neuronal cell loss than Cx3cr1+ littermate controls. Augmenting CX3CR1 signaling may protect against microglial neurotoxicity, whereas CNS penetration by pharmaceutical CX3CR1 antagonists could increase neuronal vulnerability.
Collapse
Affiliation(s)
- Astrid E Cardona
- Neuroinflammation Research Center and Department of Neurosciences, Lerner Research Institute, Cleveland, Ohio 44195, USA
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Kaul D, Gautam A, Sikand K. Importance of LXR-alpha transcriptome in the modulation of innate immunity. Mol Cell Biochem 2006; 292:53-7. [PMID: 16758300 DOI: 10.1007/s11010-006-9216-5] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2006] [Accepted: 04/21/2006] [Indexed: 11/27/2022]
Abstract
Liver-X-Receptor alpha (LXR-alpha) that belongs to nuclear receptor/transcriptional factor family has been recognized to play crucial role in the regulation of lipid metabolism and inflammation. Consequently, the present study was addressed to explore the functional genomics of LXR-alpha within human blood immunomodulatory cells. The results of such a study, which involved LXR-alpha gene silencing through siRNA approach, revealed that: (a) the mRNA expression of genes coding for IL-8, IL-4, CX3CR1, LDLR, hTERT and c-myc was significantly elevated in response to LXR-alpha gene silencing whereas mRNA expression of genes coding for PPARs(alpha, gamma), CD36 and Dicer could not be detected; (b) the expression of Receptor C( k ) protein remained unaffected; (c) the mRNA expression of IFN-gamma gene was down regulated in LXR-alpha knockdown cells. Based upon these results we propose that LXR-alpha gene plays a crucial role in the regulation of innate immunity at the genomic level.
Collapse
Affiliation(s)
- Deepak Kaul
- Molecular Biology Unit, Department of Experimental Medicine and Biotechnology, Postgraduate Institute of Medical Education and Research, Chandigarh 160012, India.
| | | | | |
Collapse
|
18
|
Atherosclerosis. Vasc Med 2006. [DOI: 10.1016/b978-0-7216-0284-4.50012-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
19
|
Mangge H, Hubmann H, Pilz S, Schauenstein K, Renner W, März W. Beyond cholesterol--inflammatory cytokines, the key mediators in atherosclerosis. Clin Chem Lab Med 2005; 42:467-74. [PMID: 15202781 DOI: 10.1515/cclm.2004.081] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
The development of atherosclerotic lesions encompasses a cascade of cellular and molecular responses that can at best be characterized as an inflammatory process, and exhibits striking similarities to autoimmune diseases, such as rheumatoid arthritis. Chemokines, cytokines and their receptors are critically involved in initiation and perpetuation of atherosclerosis, and they play important roles at all levels in the pathogenesis of this disease. In the present article, the currently available information on cytokines and chemokines as key mediators in atherosclerosis is reviewed. Furthermore, based on recent experiences of our own with very early stages of atherosclerosis, possible new ways to make use of these parameters toward improved early detection, prevention and treatment of this disease are indicated.
Collapse
Affiliation(s)
- Harald Mangge
- Clinical Institute of Medical and Chemical Laboratory Diagnosis, Medical University of Graz, Graz, Austria.
| | | | | | | | | | | |
Collapse
|
20
|
Ghilardi G, Biondi ML, Turri O, Guagnellini E, Scorza R. Internal Carotid Artery Occlusive Disease and Polymorphisms of Fractalkine Receptor CX3CR1. Stroke 2004; 35:1276-9. [PMID: 15118174 DOI: 10.1161/01.str.0000128528.56009.d4] [Citation(s) in RCA: 33] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background and Purpose—
Fractalkine (FKN), a chemokine expressed by inflamed endothelium, induces leukocyte adhesion and migration via the receptor CX3CR1. The polymorphisms V249I and T280M affect receptor expression and function. The role of FKN in atherosclerosis has been recently demonstrated. The aim of this study was to investigate a possible association between CX3CR1 polymorphisms and increased risk of internal carotid artery (ICA) occlusive disease.
Methods—
We studied 108 patients consecutively recruited for ICA occlusive disease, 84 of whom underwent operation for carotid endarterectomy, and 204 subjects without ICA occlusive disease (controls). Polymorphic genotypes were determined by polymerase chain reaction and sequencing analysis.
Results—
The adjusted odds ratio (OR) associated with the presence of the M280 (TM+MM versus TT genotype) was 0.55 (95% CI: 0.29 to 0.99;
P
=0.037). Therefore, this allele is associated with a reduced risk of ICA occlusive disease. No significant differences were observed in I249 distribution. The frequency of I249 allele was significantly higher in cases of hard plaques, which are considered more stable than soft ones (OR: 0.38; 95% CI: 0.13 to 1.05;
P
=0.037). Multiple logistic regression analysis using the common risk factors and the I249 and M280 allele variants revealed that the M280 allele was an independent risk factor for ICA stenosis (
P
=0.047).
Conclusion—
The results show that the CX3CR1 M280 is an independent genetic risk factor for ICA occlusive disease and that I249 is involved in the stability of carotid plaques. Even if obtained from a relatively limited patient series, these results might have relevant implications for treatment of ICA stenosis and possibly prevention of carotid related stroke. Further prospective cross-sectional studies are needed to confirm these results.
Collapse
Affiliation(s)
- Giorgio Ghilardi
- Dipartimento MCO, Clinica Chirurgica Generale, Università degli Studi di Milano, Polo S. Paolo, Milano, Italia.
| | | | | | | | | |
Collapse
|
21
|
Weber M, Blair E, Simpson CV, O'Hara M, Blackburn PE, Rot A, Graham GJ, Nibbs RJB. The chemokine receptor D6 constitutively traffics to and from the cell surface to internalize and degrade chemokines. Mol Biol Cell 2004; 15:2492-508. [PMID: 15004236 PMCID: PMC404040 DOI: 10.1091/mbc.e03-09-0634] [Citation(s) in RCA: 156] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/02/2003] [Revised: 02/10/2004] [Accepted: 02/12/2004] [Indexed: 11/11/2022] Open
Abstract
The D6 heptahelical membrane protein, expressed by lymphatic endothelial cells, is able to bind with high affinity to multiple proinflammatory CC chemokines. However, this binding does not allow D6 to couple to the signaling pathways activated by typical chemokine receptors such as CC-chemokine receptor-5 (CCR5). Here, we show that D6, like CCR5, can rapidly internalize chemokines. However, D6-internalized chemokines are more effectively retained intracellularly because they more readily dissociate from the receptor during vesicle acidification. These chemokines are then degraded while the receptor recycles to the cell surface. Interestingly, D6-mediated chemokine internalization occurs without bringing about a reduction in cell surface D6 levels. This is possible because unlike CCR5, D6 is predominantly localized in recycling endosomes capable of trafficking to and from the cell surface in the absence of ligand. When chemokine is present, it can enter the cells associated with D6 already destined for internalization. By this mechanism, D6 can target chemokines for degradation without the necessity for cell signaling, and without desensitizing the cell to subsequent chemokine exposure.
Collapse
Affiliation(s)
- Michele Weber
- The Cancer Research UK Beatson Laboratories, The Beatson Institute for Cancer Research, Glasgow G61 1BD, Scotland, UK
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshie O, Imai T. Fractalkine in vascular biology: from basic research to clinical disease. Arterioscler Thromb Vasc Biol 2004; 24:34-40. [PMID: 12969992 DOI: 10.1161/01.atv.0000095360.62479.1f] [Citation(s) in RCA: 236] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Fractalkine (now also called CX3CL1) is a unique chemokine that functions not only as a chemoattractant but also as an adhesion molecule and is expressed on endothelial cells activated by proinflammatory cytokines, such as interferon-gamma and tumor necrosis factor-alpha. The fractalkine receptor, CX3CR1, is expressed on cytotoxic effector lymphocytes, including natural killer (NK) cells and cytotoxic T lymphocytes, which contain high levels of intracellular perforin and granzyme B, and on macrophages. Soluble fractalkine causes migration of NK cells, cytotoxic T lymphocytes, and macrophages, whereas the membrane-bound form captures and enhances the subsequent migration of these cells in response to secondary stimulation with other chemokines. Furthermore, stimulation through membrane-bound fractalkine activates NK cells, leading to increased cytotoxicity and interferon-gamma production. Recently, accumulating evidence has shown that fractalkine is involved in the pathogenesis of various clinical disease states or processes, such as atherosclerosis, glomerulonephritis, cardiac allograft rejection, and rheumatoid arthritis. In addition, polymorphisms in CX3CR1, which reduce its binding activity to fractalkine, have been reported to increase the risk of HIV disease and to reduce the risk of coronary artery disease. This review will examine new concepts underlying fractalkine-mediated leukocyte migration and tissue damage, focusing primarily on the pathophysiological roles of fractalkine in various clinical conditions, especially in atherosclerosis and vascular injury.
Collapse
Affiliation(s)
- Hisanori Umehara
- Department of Rheumatology and Clinical Immunology, Clinical Science for Pathological Organs, Kyoto University Graduate School of Medicine, Kyoto, Japan.
| | | | | | | | | | | |
Collapse
|